COMPANY PROFILE

Alector

Combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel

San Francisco, United StatesFounded 2013Biotech & Life Sciences

Revenue $21M Latest reported FY

Total funding $100–500M Disclosed equity funding

About Alector

Alector is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company operates in the healthcare and biotechnology market, targeting a critical and growing need for effective treatments in this area. Alector's primary clients include healthcare providers, research institutions, and pharmaceutical companies that are involved in the treatment and study of neurodegenerative conditions.

Read full description

Alector's business model revolves around research and development (R&D) of novel therapeutic candidates. The company leverages insights from immunology, neurology, and human genetics to create medicines that harness the body's innate ability to heal itself. By focusing on early-stage clinical trials and gathering disease-specific data quickly, Alector aims to increase the probability of success for its therapies.

The company makes money through a combination of funding from partnerships, grants, and potential future revenues from the commercialization of its therapies. Alector's strategy includes presenting its findings at healthcare conferences and publishing data from clinical trials to attract investment and collaboration opportunities.

In summary, Alector is pioneering new treatments for neurodegenerative diseases by combining cutting-edge science with a strategic approach to drug development. Their innovative pipeline and commitment to addressing unmet medical needs position them as a key player in the biopharmaceutical industry.

Source: Dealroom company data